TP53 and myelodysplastic syndrome: Patients with MDS or AML with TP53 mutations are a distinct molecular subgroup that traditionally carry poor prognosis, but new developments including 10-day decitabine, APR-246, and mouse double minute 2 inhibitors (MDM2) stabilizers seem like promising methods to restore appropriate apoptosis in cancer lineages.